These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30253968)

  • 1. Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study.
    Fayfman M; Davis G; Duggan EW; Urrutia M; Chachkhiani D; Schindler J; Pasquel FJ; Galindo RJ; Vellanki P; Reyes-Umpierrez D; Wang H; Umpierrez GE
    J Diabetes Complications; 2018 Dec; 32(12):1091-1096. PubMed ID: 30253968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.
    Cardona S; Tsegka K; Pasquel FJ; Fayfman M; Peng L; Jacobs S; Vellanki P; Halkos M; Guyton RA; Thourani VH; Galindo RJ; Umpierrez G
    BMJ Open Diabetes Res Care; 2019; 7(1):e000703. PubMed ID: 31543976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial.
    Cardona S; Tsegka K; Pasquel FJ; Jacobs S; Halkos M; Keeling WB; Davis GM; Fayfman M; Albury B; Urrutia MA; Galindo RJ; Migdal AL; Macheers S; Guyton RA; Vellanki P; Peng L; Umpierrez GE
    Diabetes Obes Metab; 2021 Feb; 23(2):480-488. PubMed ID: 33140566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
    Masuda D; Kobayashi T; Sairyou M; Hanada H; Ohama T; Koseki M; Nishida M; Maeda N; Kihara S; Minami T; Yanagi K; Sakata Y; Yamashita S
    J Atheroscler Thromb; 2018 Jun; 25(6):512-520. PubMed ID: 29199201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
    Umpierrez GE; Gianchandani R; Smiley D; Jacobs S; Wesorick DH; Newton C; Farrokhi F; Peng L; Reyes D; Lathkar-Pradhan S; Pasquel F
    Diabetes Care; 2013 Nov; 36(11):3430-5. PubMed ID: 23877988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stress hyperglycemia in general surgery: Why should we care?
    Davis G; Fayfman M; Reyes-Umpierrez D; Hafeez S; Pasquel FJ; Vellanki P; Haw JS; Peng L; Jacobs S; Umpierrez GE
    J Diabetes Complications; 2018 Mar; 32(3):305-309. PubMed ID: 29273446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.
    Devin JK; Nian H; Celedonio JE; Wright P; Brown NJ
    J Clin Endocrinol Metab; 2020 Jan; 105(1):136-51. PubMed ID: 31529097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
    Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
    Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
    J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
    JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
    Li B; Luo YR; Tian F; Chen YD; Tian JW; Ding Y; Zhu M; Li JW; Zhang YQ; Shi WM
    Atherosclerosis; 2020 May; 300():10-18. PubMed ID: 32247073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
    Farngren J; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Aug; 20(8):1911-1920. PubMed ID: 29645341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin Versus Placebo to Reduce the Incidence and Severity of Posttransplant Diabetes Mellitus After Kidney Transplantation-A Single-center, Randomized, Double-blind Controlled Trial.
    Delos Santos RB; Hagopian JC; Chen L; Ramakrishnan M; Wijeweera H; Klein CL; Brennan DC
    Transplantation; 2023 May; 107(5):1180-1187. PubMed ID: 36279020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial.
    Nahon KJ; Doornink F; Straat ME; Botani K; Martinez-Tellez B; Abreu-Vieira G; van Klinken JB; Voortman GJ; Friesema ECH; Ruiz JR; van Velden FHP; de Geus-Oei LF; Smit F; Pereira Arias-Bouda LM; Berbée JFP; Jazet IM; Boon MR; Rensen PCN
    Diabetologia; 2018 Nov; 61(11):2386-2397. PubMed ID: 30145664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
    Marquard J; Stirban A; Schliess F; Sievers F; Welters A; Otter S; Fischer A; Wnendt S; Meissner T; Heise T; Lammert E
    Diabetes Obes Metab; 2016 Jan; 18(1):100-3. PubMed ID: 26362564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.